


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of the formula (I) :



and pharmaceutically acceptable salts thereof,
wherein:

A is R'-C(O)-, wherein R' is



each R¹ is independently selected from -C(O)-, -S(O)₂-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)₂, -NR²-, -NR²-S(O)₂-, -NR²-C(O)- or -NR²-C(O)-C(O)-;

each Ht is independently selected from C₃-C₇ cycloalkyl; C₅-C₇ cycloalkenyl; C₆-C₁₄ aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R²), O, S and S(O)_n; wherein

said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR², SR², -R², -N(R²)(R²), -R²-OH, -CN, -CO₂R², -C(O)-N(R²)₂, -S(O)₂-N(R²)₂, -N(R²)-C(O)-R², -N(R²)-C(O)O-R², -C(O)-R², -S(O)_n-R², -OCF₃, -S(O)_n-Q, methylenedioxy, -N(R²)-S(O)₂(R²), halo, -CF₃, -NO₂, Q, -OQ, -OR⁷, -SR⁷, -R⁷, -N(R²)(R⁷) or -N(R⁷)₂; each R² is independently selected from H, or C₁-C₄ alkyl optionally substituted with a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R³³); wherein any of said ring systems or N(R³³) is optionally substituted with 1 to 4 substituents independently selected from -X'-Y', -O-arylalkyl, -S-arylalkyl, -N(Y')₂, -N(H)-arylalkyl, -N(C₁-C₄ alkyl)-arylalkyl, oxo, -O-(C₁-C₄ alkyl), OH, C₁-C₄ alkyl, -SO₂H, -SO₂-(C₁-C₄ alkyl), -SO₂-NH₂, -SO₂-NH(C₁-C₄ alkyl), -SO₂-N(C₁-C₄ alkyl)₂, -NH₂, -NH(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)₂, -NH-C(O)H, -N(C₁-C₄ alkyl)-C(O)H, -NH-C(O)-C₁-C₄ alkyl, -C₁-C₄ alkyl-OH, -OH, -CN, -C(O)OH, -C(O)O-C₁-C₄ alkyl, -C(O)-NH₂, -C(O)-NH(C₁-C₄ alkyl), -C(O)-N(C₁-C₄ alkyl)₂, halo or -CF₃; X' is -O-, -S-, -NH-, -NHC(O)-, -NHC(O)O-, -NHSO₂-, or -N(C₁-C₄)alkyl;

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

Y' is C₁-C₁₅ alkyl, C₂-C₁₅ alkenyl or alkynyl, wherein one to five carbon atoms in Y are optionally substituted with C₃-C₇ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each R³ is independently selected from H, Ht, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl; wherein any member of said R³, except H, is optionally substituted with one or more substituents selected from -OR², -C(O)-N(R²)₂, -S(O)_n-N(R²)₂, -N(R²)₂, -N(R²)-C(O)O(R²), -N(R²)-C(O)N(R²)₂, -N(R²)-C(O)-R², Ht, -CN, -SR², -C(O)OR², N(R²)-C(O)-R²;

each R³³ is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each n is independently 1 or 2;

G, when present, is selected from H, R⁷ or C₁-C₄ alkyl, or, when G is C₁-C₄ alkyl, G and R⁷ are bound to one another either directly or through a C₁-C₃ linker to form a heterocyclic ring; or

when G is not present (i.e., when x in (G)_x is 0), then the nitrogen to which G is attached is bound directly to

the R⁷ group in -OR⁷ with the concomitant displacement of one -ZM group from R⁷;

D is selected from C₁-C₆ alkyl which is substituted with Q, which is optionally substituted with one or more groups selected from C₃-C₆ cycloalkyl, -R³, -O-Q or Q; C₂-C₄ alkenyl which is substituted with Q, which is optionally substituted with one or more groups selected from -OR², -S-Ht, -R³, -O-Q or Q; C₃-C₆ cycloalkyl, which is optionally substituted with or fused to Q; or C₅-C₆ cycloalkenyl, which is optionally substituted with or fused to Q;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R²); wherein Q contains one substituent selected from -OR², -OR⁸, -O-arylalkyl, -SR⁸, -S-arylalkyl, -N(R²)R⁸ [[,]] or -N(R²)-arylalkyl and may be optionally substituted with one or more additional substituents independently selected from oxo, -OR⁸, -O-arylalkyl -SR⁸, -S-arylalkyl, -N(R²)R⁸, -N(R²)-arylalkyl, -OR², -R², -SO₂R², -SO₂-N(R²)₂, -N(R²)₂, -N(R²)-C(O)-R², -OH, (C₁-C₄)-OH, -CN, -CO₂R², -C(O)-N(R²)₂, halo or -CF₃;

each R⁸ is independently selected from Ht, -C₁-C₁₅

branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R⁸ is additionally and optionally substituted with one or more groups independently selected from -OH, -S(C₁-C₆ alkyl), -CN, -CF₃, -N(R²)₂, halo, -C₁-C₄-alkyl, -C₁-C₄-alkoxy; -Ht; -O-Ht; -NR²-CO-N(R²)₂; -CO-N(R²)₂; -R¹-C₂-C₆ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C₁-C₄ alkoxy, Ht, -O-Ht, -NR²-CO-N(R²)₂ or -CO-N(R²)₂; or R⁷;

wherein W is -O-, -NR²-, -S-, -C(O)-, -C(S)-, -C(=NR²)-, -S(O)₂-, -NR²-S(O)₂-, -S(O)₂-NR²-, -NR²-C(O)O-, -O-C(O)NR²-, -NR²-C(O)NR²-, -NR²-C(S)NR²-, -CONR², -NR²C(O)-, -C(S)NR², -NR²C(S)-, -NR²-C(=N-CN)-NR²-, -NR²C(=N-CN)O- or -C(O)O-;

D' is selected from C₁-C₁₅ alkyl, C₁-C₁₅ alkoxy, C₂-C₁₅ alkenyl, C₂-C₁₅ alkenyloxy, C₂-C₁₅ alkynyl, or C₂-C₁₅ alkynyloxy, wherein D' optionally comprises one or more substituents independently selected from Ht, oxo, halo, -CF₃, -OCF₃, -NO₂, azido, -SH, -SR³, -N(R³)-N(R³)₂, -O-N(R³)₂, -(R³)N-O-(R³), -N(R³)₂, -CN, -CO₂R³, -C(O)-N(R³)₂, -S(O)_n-N(R³)₂, -N(R³)-C(O)-R³, -N(R³)-C(O)-N(R³)₂, -C(O)-R³, -S(O)_n-R³, -N(R³)-S(O)_n(R³), -N(R³)-S(O)_n-N(R³)₂, -S-NR³-C(O)R³, -C(S)N(R³)₂, -C(S)R³, -NR³-C(O)OR³, -O-C(O)OR³, -O-C(O)N(R³)₂, -NR³-C(S)R³, =N-OH,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

=N-OR³, =N-N(R³)₂, =NR³, =NNR³C(O)N(R³)₂, =NNR³C(O)OR³,
=NNR³S(O)_n-N(R³)₂, -NR³-C(S)OR³, -NR³-C(S)N(R³)₂,
-NR³-C[=N(R³)]-N(R³)₂, -N(R³)-C[=N-NO₂]-N(R³)₂,
-N(R³)-C[=N-NO₂]-OR³, -OC(O)R³, -OC(S)R³, -OC(O)N(R³)₂,
-C(O)N(R³)-N(R³)₂, -N(R³)-N(R³)C(O)R³, -N(R³)-OC(O)R³,
-N(R³)-OC(O)R³, -N(R³)-OC(O)R³, -OC(S)N(R³)₂, -OC(S)N(R³)(R³), or
-PO₃-R³;

E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; -O-R³; -N(R²)(R³); -N(R²)-Ht; C₁-C₆ alkyl, which is optionally substituted with one or more groups selected from R⁴ or Ht; C₂-C₆ alkenyl, which is optionally substituted with one or more groups selected from R⁴ or Ht; C₃-C₆ saturated carbocycle, which is optionally substituted with one or more groups selected from R⁴ or Ht; or C₅-C₆ unsaturated carbocycle, which is optionally substituted with one or more groups selected from R⁴ or Ht;

each R⁴ is independently selected from -R², -OR², -OR³, -SR², -SOR², -SO₂R², -CO₂R², -OC(O)-R², -C(O)-N(R²)₂, -C(O)-NR²(OR²), -S(O)₂-N(R²)₂, halo, -NR²-C(O)-R², -NR²-OR², -N(R²)₂ or -CN;

each R⁷ is independently selected from hydrogen,



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R²)₄, C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, or -R⁶; wherein 1 to 4 -CH₂ radicals of the alkyl or alkenyl group, other than the -CH₂ that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O), S(O₂), or N(R²); and wherein any hydrogen in said alkyl, alkenyl or R⁶ is optionally replaced with a substituent selected from oxo, -C₁-C₄ alkyl, -N(R²)₂, -N(R²)₃, -OH, -O-(C₁-C₄ alkyl), -CN, -C(O)OR², -C(O)-N(R²)₂, S(O)₂-N(R²)₂, -N(R²)-C(O)-R₂, C(O)R², -S(O)_n-R², -OCF₃, -S(O)_n-R⁶, -N(R²)-S(O)₂(R²), halo, -CF₃, or -NO₂;

M' is H, C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, or -R⁶; wherein 1 to 4 -CH₂ radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), S(O₂), or N(R²); and wherein any hydrogen in said alkyl, alkenyl or R⁶ is optionally replaced with a substituent selected from oxo, -OR², -C₁-C₄ alkyl, -N(R²)₂, N(R²)₃, -OH, -O-(C₁-C₄ alkyl), -CN, -C(O)OR², -C(O)-N(R²)₂, -S(O)₂-N(R²)₂, -N(R²)-C(O)-R₂, -C(O)R², -S(O)_n-R², -OCF₃, -S(O)_n-R⁶, -N(R²)-S(O)₂(R²), halo, -CF₃, or -NO₂;

x is 0 or 1;

Z is O, S, N(R²)₂, or, when M is not present, H;

Y is P or S;

X is O or S; and

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

R^9 is $C(R^2)_2$, O or $N(R^2)$; and wherein when Y is S, Z is not S; and

R^6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, $S(O)_n$ or $N(R^2)$; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, $-C_1-C_4$ alkyl, $-O-(C_1-C_4$ alkyl) or $-O-C(O)-(C_1-C_4$ alkyl).

2. (Original) The compound according to claim 1, wherein R^8 is $-C_1-C_4$ -branched or straight chain alkyl, wherein one to two carbon atoms in said alkyl are independently replaced by W, wherein R^8 is additionally and optionally substituted with one or more groups independently selected from -OH; $-C_1-C_4$ -alkoxy; -Ht; $-O-Ht$; $-NR^2-CO-N(R^2)_2$; $-CO-N(R^2)_2$; $-R^1-C_2-C_6$ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C_1-C_4 alkoxy, Ht, $-O-Ht$, $-NR^2-CO-N(R^2)_2$ or $-CO-N(R^2)_2$; or R^7 ; wherein W is $-O-$, $-NR^2-$, $-NR^2-S(O)_2-$, $-NR^2-C(O)O-$, $-O-C(O)NR^2-$, $-NR^2-C(O)NR^2-$, $-NR^2-C(S)NR^2-$, $-NR^2C(O)-$, $-C(=NR^2)-$, $-C(O)NR^2-$, $-NR^2-C(=N-CN)-NR^2-$, $-NR^2C(=N-CN)O-$ or $-C(O)O-$; and


wherein Ht, R¹, R² and R⁷ are as defined in claim 1.

3. (Previously presented) The compound according to claim 1, wherein R⁸ is a -C₁-C₄-branched or straight alkyl chain, wherein one to two carbon atoms are substituted with Ht;


wherein Ht is C₆₋₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R²), O, S and S(O)_n, wherein any member of Ht is optionally substituted with one or more substituents independently selected from oxo, -OR², SR², -R², -N(R²)(R²), -R²-OH, -CN, -CO₂R², -C(O)-N(R²)₂, -S(O)₂-N(R²)₂, -N(R²)-C(O)-R², -N(R²)-C(O)O-R², -C(O)-R², -S(O)_n-R², -OCF₃, -S(O)_n-Q, methylenedioxy, -N(R²)-S(O)₂(R²), halo, -CF₃, -NO₂, Q, -OQ, -OR⁷, -SR⁷, -R⁷, -N(R²)(R⁷) or -N(R⁷)₂.

4. (Currently amended) The compound according to claim 1, wherein R⁸ is selected from:


Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action





Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action




5. (Original) The compound according to claim 1,
wherein at least one R⁷ is selected from:





Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action



acetyl, , , -(L)-valine, -(L)-glutamic acid,

-(L)-aspartic acid, -(L)- γ -t-butyl-aspartic acid, 

-(L)-(L)-3-pyridylalanine, -(L)-histidine, -CHO, 



PO_3 -spermine, PO_3 -(spermidine)₂ or PO_3 -(meglamine)₂.


6. (Canceled).

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

7. (Previously presented) The compound according to claim 1, wherein:

D' is -CH₂-R'', wherein R'' is selected from:


isobutyl, ;



wherein m is 0 to 3.


8. (Previously presented) The compound according to claim 1, wherein:

E is selected from:



9. (Currently amended) A compound having the


formula (II):



and pharmaceutically acceptable salts thereof;

wherein:

A is selected from R' -C(O) -, wherein R' is



each R¹ is independently selected from -C(O) -, -S(O)₂ -, -C(O) -C(O) -, -O-C(O) -, -O-S(O)₂ -, -NR² -, -NR² -S(O)₂ -, -NR² -C(O) - or -NR² -C(O) -C(O) -;

each Ht is independently selected from C₃-C₇ cycloalkyl; C₅-C₇ cycloalkenyl; C₆-C₁₄ aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, N(R²), O, S and S(O)_n; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR²,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

SR^2 , $-R^2$, $-N(R^2)(R^2)$, $-R^2-OH$, $-CN$, $-CO_2R^2$, $-C(O)-N(R^2)_2$,
 $-S(O)_2-N(R^2)_2$, $-N(R^2)-C(O)-R^2$, $-N(R^2)-C(O)O-R^2$, $-C(O)-R^2$,
 $-S(O)_n-R^2$, $-OCF_3$, $-S(O)_n-Q$, methylenedioxy, $-N(R^2)-S(O)_2(R^2)$,
halo, $-CF_3$, $-NO_2$, Q , $-OQ$, $-OR^7$, $-SR^7$, $-R^7$, $-N(R^2)(R^7)$ or $-N(R^7)_2$;
each R^2 is independently selected from H, or C_1-C_4
alkyl optionally substituted with a 3-7 membered saturated,
partially saturated or unsaturated carbocyclic ring system; or
a 5-7 membered saturated, partially saturated or unsaturated
heterocyclic ring containing one or more heteroatoms selected
from O, N, S, $S(O)_n$ or $N(R^{33})$; wherein any of said ring systems
or $N(R^{33})$ is optionally substituted with 1 to 4 substituents
independently selected from $-X'-Y'$, $-O-arylalkyl$,
 $-S-arylalkyl$, $-N(Y')_2$, $-N(H)-arylalkyl$, $-N(C_1-C_4$
alkyl)-arylalkyl, oxo, $-O-(C_1-C_4$ alkyl), OH, C_1-C_4 alkyl, $-SO_2H$,
 $-SO_2-(C_1-C_4$ alkyl), $-SO_2-NH_2$, $-SO_2-NH(C_1-C_4$ alkyl), $-SO_2-N(C_1-C_4$
alkyl) $_2$, $-NH_2$, $-NH(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl) $_2$, $-NH-C(O)H$,
 $-N(C_1-C_4$ alkyl)- $C(O)H$, $-NH-C(O)-C_1-C_4$ alkyl, $-C_1-C_4$ alkyl-OH,
 $-OH$, $-CN$, $-C(O)OH$, $-C(O)O-C_1-C_4$ alkyl, $-C(O)-NH_2$,
 $-C(O)-NH(C_1-C_4$ alkyl), $-C(O)-N(C_1-C_4$ alkyl) $_2$, halo or $-CF_3$;
 X' is $-O-$, $-S-$, $-NH-$, $-NHC(O)-$, $-NHC(O)O-$, $-NHSO_2-$,
or $-N(C_1-C_4)$ alkyl-;

Y' is C_1-C_{15} alkyl, C_2-C_{15} alkenyl or alkynyl, wherein
one to five carbon atoms in Y are optionally substituted with
 C_3-C_7 cycloalkyl or C_5-C_6 cycloalkenyl, C_6-C_{14} aryl or a 5-7

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each R³ is independently selected from H, Ht, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl; wherein any member of said R³, except H, is optionally substituted with one or more substituents selected from -OR², -C(O)-N(R²)₂, -S(O)_n-N(R²)₂, -N(R²)₂, -N(R²)-C(O)O(R²), -N(R²)-C(O)N(R²)₂, -N(R²)-C(O)-R², Ht, -CN, -SR², -C(O)OR², N(R²)-C(O)-R²;

each R³³ is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl or C₅-C₆ cycloalkenyl, C₆-C₁₄ aryl or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N, NH, O, S and S(O)_n;

each n is independently 1 or 2;

each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S, S(O)_n or N(R²); wherein Q contains one substituent selected from -OR², -OR⁸, -O-arylalkyl, -SR⁸, -S-arylalkyl, -N(R²)R⁸ [[,]] or -N(R²)-arylalkyl and may be optionally substituted with one or more additional substituents independently selected from 'oxo,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

-OR⁸, -O-arylalkyl -SR⁸, -S-arylalkyl, -N(R²)R⁸, -N(R²)-arylalkyl, -OR², -R², -SO₂R², -SO₂-N(R²)₂, -N(R²)₂, -N(R²)-C(O)-R², -OH, (C₁-C₄)-OH, -CN, -CO₂R², -C(O)-N(R²)₂, halo or -CF₃;

each R⁸ is independently selected from Ht, -C₁-C₁₅ branched or straight chain alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are independently replaced by W, or wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl are substituted with Ht; and wherein R⁸ is additionally and optionally substituted with one or more groups independently selected from -OH, -S(C₁-C₆ alkyl), -CN, -CF₃, -N(R²)₂, halo, -C₁-C₄-alkyl, -C₁-C₄-alkoxy; -Ht; -O-Ht; -NR²-CO-N(R²)₂; -CO-N(R²)₂; -R¹-C₂-C₆ alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy, C₁-C₄ alkoxy, Ht, -O-Ht, -NR²-CO-N(R²)₂ or -CO-N(R²)₂; or R⁷;

wherein W is -O-, -NR²-, -S-, -C(O)-, -C(S)-, -C(=NR²)-, -S(O)₂-, -NR²-S(O)₂-, -S(O)₂-NR²-, -NR²-C(O)O-, -O-C(O)NR²-, -NR²-C(O)NR²-, -NR²-C(S)NR²-, -CONR², -NR²C(O)-, -C(S)NR², -NR²C(S)-, -NR²-C(=N-CN)-NR²-, -NR²C(=N-CN)O- or -C(O)O-;

D' is selected from C₁-C₁₅ alkyl, C₁-C₁₅ alkoxy, C₂-C₁₅ alkenyl, C₂-C₁₅ alkenyloxy, C₂-C₁₅ alkynyl, or C₂-C₁₅ alkynyloxy, wherein D' optionally comprises one or more substituents independently selected from Ht, oxo, halo, -CF₃, -OCF₃, -NO₂,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

azido, -SH, -SR³, -N(R³)-N(R³)₂, -O-N(R³)₂, -(R³)N-O-(R³), -N(R³)₂, -CN, -CO₂R³, -C(O)-N(R³)₂, -S(O)_n-N(R³)₂, -N(R³)-C(O)-R³, -N(R³)-C(O)-N(R³)₂, -C(O)-R³, -S(O)_n-R³, -N(R³)-S(O)_n(R³), -N(R³)-S(O)_n-N(R³)₂, -S-NR³-C(O)R³, -C(S)N(R³)₂, -C(S)R³, -NR³-C(O)OR³, -O-C(O)OR³, -O-C(O)N(R³)₂, -NR³-C(S)R³, =N-OH, =N-OR³, =N-N(R³)₂, =NR³, =NNR³C(O)N(R³)₂, =NNR³C(O)OR³, =NNR³S(O)_n-N(R³)₂, -NR³-C(S)OR³, -NR³-C(S)N(R³)₂, -NR³-C[=N(R³)]-N(R³)₂, -N(R³)-C[=N-NO₂]-N(R³)₂, -N(R³)-C[=N-NO₂]-OR³, -OC(O)R³, -OC(S)R³, -OC(O)N(R³)₂, -C(O)N(R³)-N(R³)₂, -N(R³)-N(R³)C(O)R³, -N(R³)-OC(O)R³, -N(R³)-OC(O)R³, -N(R³)-OC(S)N(R³)₂, -OC(S)N(R³)(R³), or -PO₃-R³;


E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht; -O-R³; -N(R²)(R³); -N(R²)-Ht; C₁-C₆ alkyl, which is optionally substituted with one or more groups selected from R⁴ or Ht; C₂-C₆ alkenyl, which is optionally substituted with one or more groups selected from R⁴ or Ht; C₃-C₆ saturated carbocycle, which is optionally substituted with one or more groups selected from R⁴ or Ht; or C₅-C₆ unsaturated carbocycle, which is optionally substituted with one or more groups selected from R⁴ or Ht;

each R⁴ is independently selected from -R², -OR², -OR³, -SR², -SOR², -SO₂R², -CO₂R², -OC(O)-R², -C(O)-N(R²)₂, -C(O)-NR²(OR²), -S(O)₂-N(R²)₂, halo, -NR²-C(O)-R², -NR²-OR²,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

$-\text{N}(\text{R}^2)_2$ or $-\text{CN}$;

each R^7 is independently selected from hydrogen,



from H, Li, Na, K, Mg, Ca, Ba, $-\text{N}(\text{R}^2)_4$, $\text{C}_1\text{-C}_{12}$ -alkyl, $\text{C}_2\text{-C}_{12}$ -alkenyl, or $-\text{R}^6$; wherein 1 to 4 $-\text{CH}_2$ radicals of the alkyl or alkenyl group, other than the $-\text{CH}_2$ that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O) , $\text{S(O}_2\text{)}$, or $\text{N}(\text{R}^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, $-\text{C}_1\text{-C}_4$ alkyl, $-\text{N}(\text{R}^2)_2$, $-\text{N}(\text{R}^2)_3$, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_4$ alkyl), $-\text{CN}$, $-\text{C(O)OR}^2$, $-\text{C(O)-N}(\text{R}^2)_2$, $\text{S(O)}_2\text{-N}(\text{R}^2)_2$, $-\text{N}(\text{R}^2)\text{-C(O)-R}_2$, C(O)R^2 , $-\text{S(O)}_n\text{-R}^2$, $-\text{OCF}_3$, $-\text{S(O)}_n\text{-R}^6$, $-\text{N}(\text{R}^2)\text{-S(O)}_2\text{(R}^2\text{)}$, halo, $-\text{CF}_3$, or $-\text{NO}_2$;

M' is H, $\text{C}_1\text{-C}_{12}$ -alkyl, $\text{C}_2\text{-C}_{12}$ -alkenyl, or $-\text{R}^6$; wherein 1 to 4 $-\text{CH}_2$ radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O) , $\text{S(O}_2\text{)}$, or $\text{N}(\text{R}^2)$; and wherein any hydrogen in said alkyl, alkenyl or R^6 is optionally replaced with a substituent selected from oxo, $-\text{OR}^2$, $-\text{C}_1\text{-C}_4$ alkyl, $-\text{N}(\text{R}^2)_2$, $\text{N}(\text{R}^2)_3$, $-\text{OH}$, $-\text{O}-(\text{C}_1\text{-C}_4$ alkyl), $-\text{CN}$, $-\text{C(O)OR}^2$, $-\text{C(O)-N}(\text{R}^2)_2$, $-\text{S(O)}_2\text{-N}(\text{R}^2)_2$,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

-N(R²)-C(O)-R₂, -C(O)R², -S(O)_n-R², -OCF₃, -S(O)_n-R⁶,

-N(R²)-S(O)₂(R²), halo, -CF₃, or -NO₂;

x is 0 or 1;

Z is O, S, N(R²)₂, or, when M is not present, H;












Y is P or S;

X is O or S; and

R⁹ is C(R²)₂, O or N(R²); and wherein when Y is S, Z is not S; and



R⁶ is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, S(O)_n or N(R²); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from -OH, -C₁-C₄ alkyl, -O-(C₁-C₄ alkyl) or -O-C(O)-(C₁-C₄ alkyl).

10. (Original) The compound according to claim 9, wherein R⁸ is selected from:




, or

11. (Currently amended) The compound according to claim 9, wherein R⁸ is selected from:




or




12. (Original) The compound according to claim 9,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action


wherein R⁸ is selected from:



13. (Original) The compound according to claim 9,
wherein R⁸ is selected from:








Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action




, or

14. (Previously presented) The compound according to claim 9, wherein R⁸ is selected from:



, or

15. (Currently amended) The compound according to claim 9, wherein said compound is selected from compound numbers: 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, 71, 72, 73, 74, 202, 203, 209, 213, 215, 223, 227, 231, 233, 236, 237, 239, 243, 247, 250, 260, 263, 271, 281, 289, 293, 295, 309, 317, 319, 320, 322, 334, 335, 348, 364, 367, 368, 375, 382, 383 and 396, wherein said compound numbers are as defined below: [..]



A	$S(O)_2E$	R^8
26		
27		
31		

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action


A	S (O) ₂ E	R ⁸
33		
35		
36		
38		
41		
43		
48		
49		

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

A	S (O) ₂ E	R ⁸
51		
52		
53		
54		
55		
56		
57		
59		



Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

A	$S(O)_2E$	R^8	
60			



A	$S(O)_2E$	R^8	
71			
72			
73			

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action





























	A	R^8	D'	E
202				
203				
209				
213				
215				
223				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action


227				
231				
233				
236				
237				
239				
243				
247				
250				
260				
263				
271				
281				
289				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

293				
295				
309				
317				
319				
320				
322				
334				
335				
348				
364				
367				
368				

375				
382				
383				
396				






















16. (Currently amended) The compound according to claim 15, wherein said compound is selected from compound numbers: 26, 27, 31, 33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 59, 60, 71, 72, 73, 74, 209, 215, 227, 233, 237, 281, 289, 295, 309, 322, 335, 364, 368, 382 and 383,
wherein said compound numbers are as defined below: [[.]]






Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

A	$S(O)_2E$	R^8
26		
27		
31		
33		
35		
36		
38		
41		

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action


43			
48			
49			
51			
52			
53			
54			
55			
56			

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action



Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

A	$S(O)_2E$	R^8
73		
74		




	A	R^8	D'	E
209				
215				
227				
233				
237				


281				
289				
295				
309				
322				
335				
364				
368				
382				
383				

17. (Currently amended) The compound according to claim 16, wherein said compound is selected from compound numbers: 54, 209, 237, 281, 295, 309, and 368, wherein the compound numbers are as defined below: [.]

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action



	A	$S(O)_2E$	R^8
54			



	A	R^8	D'	E
209				
237				
281				

295				
309		-CONHMe		
368				

18. (Previously presented) A composition comprising a compound according to claim 1 or 9, in an amount sufficient to inhibit an aspartyl protease; and a pharmaceutically acceptable carrier.

19. (Original) The composition according to claim 18, wherein said composition is in a pharmaceutically acceptable form for administration to a human being.

20. (Original) The composition according to claim 18, wherein said composition additionally comprises an additional anti-viral agent.

21. (Original) The composition according to claim 18, wherein said composition comprises at least one additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]- guanine [(-)BHCG, SQ-

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl)guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone, 3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429);

interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxyfylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD4 and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293).

22. (Previously presented) The composition according to claim 18, wherein said composition is in an orally available dosage form.

23. (Withdrawn) A method of treating a patient infected with a virus that depends upon an aspartyl protease for an obligatory event in its life cycle comprising the step

of administering to said patient a composition according to
claim 18.

24. (Withdrawn) A method of treating a patient
infected with HIV-I or HIV-II comprising the step of
administering to said patient a composition according to claim
18.

25. (Withdrawn) The method according to claim 23,
comprising the additional step of administering to said
patient an additional therapeutic agent selected from (1
alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)
cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis-
(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides,
such as acyclovir, valaciclovir, famciclovir, ganciclovir or
penciclovir; acyclic nucleoside phosphonates, such as (S)-1-
(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC);
ribonucleotide reductase inhibitors, such as 2-acetylpyridine
5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone,
3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such
as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-
dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl
protease inhibitors, such as indinavir, ritonavir, nelfinavir,
or [3S- [3R* (1R*, 2S*)]]-[3[[(4-aminophenyl)sulfonyl] (2-

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD₄ and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

26. (Withdrawn) A method of treating a patient diagnosed with AIDS; AIDS related complex (ARC); progressive generalized lymphadenopathy (PGL); Kaposi's sarcoma, thrombocytopenic purpura; AIDS-related neurological conditions such as AIDS dementia complex, multiple sclerosis or tropical paraparesis; anti-HIV antibody-positive conditions; or HIV-positive conditions, comprising the step of administering to said patient a composition according to claim 18.


27. (Withdrawn) The method according to claim 26, comprising the additional step of administering to said patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)BHCG, SQ-34514]; oxetanocin-G (3,4-bis(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or

penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl] thiocarbonohydrazone, 3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD4 and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

28. (Currently amended) The compound according to claim 15, wherein said compound is compound number 368,
wherein said compound number is as defined below: [.]



	A	R ⁸	D'	E
368				

29. (Previously presented) The composition according to claim 19, wherein said composition is in an orally available dosage form.

30. (Previously presented) The composition according to claim 20, wherein said composition is in an orally available dosage form.

31. (Previously presented) The composition according to claim 21, wherein said composition is in an orally available dosage form.

32. (Withdrawn) The method according to claim 24, comprising the additional step of administering to said

patient an additional therapeutic agent selected from (1 alpha, 2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine [(-)-BHCG, SQ-34514]; oxetanocin-G (3,4-bis(hydroxymethyl)-2-oxetanosyl]guanine); acyclic nucleosides, such as acyclovir, valaciclovir, famciclovir, ganciclovir or penciclovir; acyclic nucleoside phosphonates, such as (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC); ribonucleotide reductase inhibitors, such as 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone, 3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl protease inhibitors, such as indinavir, ritonavir, nelfinavir, or [3S-[3R*(1R*, 2S*)]]-[3[[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir); oxathiolane nucleoside analogues, such as (-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine (lamivudine) or cis-1-(2-hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine; 5-chloro-2',3'-dideoxy-3'-fluorouridine; (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat inhibitors, such as 7-chloro-5-(2-pyrryl)-3H-1,4-

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action


benzodiazepin-2-(H)one (Ro5-3335) or 7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine (Ro24-7429); interferons, such as α -interferon; renal excretion inhibitors such as probenecid; nucleoside transport inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine (NAC); Procysteine; α -trichosanthin; phosphonoformic acid; immunomodulators, such as interleukin II or thymosin; granulocyte macrophage colony stimulating factors; erythropoetin; soluble CD₄ and genetically engineered derivatives thereof; non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587), loviride (α -APA) or delavuridine (BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such as isopropyl (2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said additional agent is administered to said patient as either a separate dosage form or as a single dosage form together with said compound.

33. (Currently amended) A compound selected from compound numbers: 26, 27, 28, 29, 30, 31, 32, 32, 33, 34, 35,

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 71, 72, 73,
74, 75, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,
212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223,
224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235,
236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247,
248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259,
260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271,
272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283,
284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295,
296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 309, 310,
311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322,
323, 324, 326, 327, 329, 331, 332, 333, 334, 335, 336, 337,
338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349,
351, 352, 353, 354, 355, 356, 357, 358, 359, 361, 364, 365,
366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377,
378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389,
390, 391, 392, 393, 394, 395, 396, 397 and 398, wherein said
compound numbers are as defined below: [.]

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action




A	<i>S</i> (O) ₂ E	R ^B
26		
27		
28		
29		
30		
31		

Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action

32			H
33			
34			
35			
36			
37			
38			
39			H
40			




Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action









Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action


51			
52			
53			
54			
55			
56			
57			
59			
60			




Appln. No. 10/691,333
Reply dated November 14, 2007
In response to May 14, 2007 Office Action



Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

A	$S(O)_2E$	R^8
73		
74		
75		



	A	R^8	D'	E
201		$-H$		
202				
203				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

204				
205				
206				
207				
208				
209				
210				
211				
212				
213				
214				
215				
216				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

217				
218				
219				
220				
221				
222				
223				
224				
225				
226				
227				
228				
229				
230				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

231				
232				
233				
234				
235				
236				
237				
238				
239				
240				
241				
242				
243				
244				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

245				
246				
247				
248				
249				
250				
251				
252				
253				
254				
255				
256				
257				
258				


































Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

259				
260				
261				
262				
263				
264				
265				
266				
267				
268				
269				
270				
271				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

272				
273				
274				
275				
276				
277				
278				
279				
280				
281				
282				
283				
284				
285				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

286				
287				
288				
289				
290				
291		H		
292				
293				
294				
295				
296				
297				
298				























299				
300				
301				
302				
303				
304				
305				
309				
310				
311				
312				
313				
314				
315				

316				
317				
318				
319				
320				
321				
322				
323				
324				
326				
327				
329				
331				
332				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

333				
334				
335				
336				
337				
338				
339				
340				
341				
342				
343				
344				
345				

346				
347				
348				
349				
351		H		
352				
353				
354				
355				
356				
357				
358				
359				
361				

364				
365				
366				
367				
368				
369				
370				
371				
372				
373				
374				
375				

376				
377				
378				
379				
380				
381				
382				
383				
384				
385				
386				
387				
388				

Appln. No. 10/691,333
 Reply dated November 14, 2007
 In response to May 14, 2007 Office Action

389				
390				
391				
392				
393				
394				
395				
396				
397				
398				